Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1α

Figure 2

Dose- and time-dependent responses of wild-type EGFR and tyrosine kinase domain-mutated EGFR cells to cetuximab and gefitinib treatment. (a) Absolute cell numbers in each treatment group (control [DMSO]), 5 nM cetuximab, and 0.5 μM gefitinib, all in 0.5% FBS medium) were plotted against the duration of treatment. (b) The inhibition of cell proliferation after treatment with cetuximab was measured by an MTT assay and is shown as a percentage of the optical density value of control cells (untreated) for each concentration tested. (c) The inhibition of cell proliferation after treatment with gefitinib was measured as in (b) and is shown as a percentage of the optical density value of vehicle-treated cells (DMSO) for each concentration tested. Results are shown as the mean of five independent measurements, plus or minus the standard deviation (SD). The magnitude of some SDs was smaller than the symbol size; thus some bars do not appear in the figure.

Back to article page

Molecular Cancer

ISSN: 1476-4598